JANX - Multiplikator P/S Janux Pharma

Tandha merek Janux Corp (JANX)

Janux Therapeutics (JANX) develops targeted cancer therapies for clinics, which is reflected in the company's P/S ratio. The value of 29.80 represents the current metric. Leading scientists, incentivized by stock options, drive the development process. Due to its insulation from macroeconomic volatility and steady demand for innovation, the business serves as a defensive asset during recessionary periods.

JANX (Janux Pharma) riwayat Rasio rega marang pendapatan saka 04.07.2022 nganti 15.11.2026

Janux Pharma (JANX) - rincian metrik lan laporan keuangan

- rega pasar lan target rega analis:
Analisis umum perusahaan:Janux Therapeutics, Inc., JANX
Produk asil prodhuksi Janux Therapeutics Inc

The P/S multiple reflects the market value of the business relative to its annual revenue, allowing for an assessment of the asset's investment attractiveness under tight monetary policy. By analyzing the price/sales ratio dynamics, an investor can see the sensitivity of capitalization to revenue, which, for the asset-light model of Janux Therapeutics (JANX) utilizing outsourced production, emphasizes that the valuation depends on R&D efficiency rather than the ownership of physical capacities.

Perusahaan pesaing

Kapitalisasi marang pendapatan ImmunityBio Corp IBRX|Immunocore Holdings - Kapitalisasi marang pendapatan|Multiplikator P/S Arcus Corp RCUS|ZYME - Rasio rega marang pendapatan|TNGX (tangotx.com) - Rasio kapitalisasi marang pendapatan|Iovance Corp (IOVA) - Rasio rega marang pendapatan|Rega marang dodolan Immatics Corp (IMTX)|Kapitalisasi marang pendapatan XNCR|CMPX - Multiplikator rega marang pendapatan|Kapitalisasi marang pendapatan REPL (Replimune Corp)|Kapitalisasi marang volume dodolan LYEL|Multiplikator P/S IPHA (Innate Pharma)|Rasio kapitalisasi pasar marang pendapatan PYXS|Compugen Limited - Multiplikator P/S|Rega marang dodolan IO Biotech Inc.|Sutro Biopharma, Inc. (STRO) - Rasio rega marang pendapatan|MiNK Therapeutics, Inc. - Rasio kapitalisasi pasar marang pendapatan|HOWL (Werewolf) - Multiplikator P/S|Multiplikator P/S immixbio.com|Rasio rega marang pendapatan ALX Oncology Holdings (ALXO)|CUE - Rega marang dodolan|PDS Biotechnology Corporation - Kapitalisasi marang pendapatan|Sonnet BioTherapeutics (SONN) - Rega marang dodolan|MAIA - Rasio rega marang pendapatan|LIMN: Rasio rega marang pendapatan|LVTX: Multiplikator P/S|Rega marang dodolan NextCure, Inc. (NXTC)|LPTX (Leap Tx) - Multiplikator P/S|INTS (Intensity Therapeutics) - Kapitalisasi marang volume dodolan|Rasio rega marang pendapatan Sensei Bio (SNSE)|TOVX (Theriva Biologics) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan gritstonebio.com GRTS|Rasio kapitalisasi pasar marang pendapatan KA|NEXI - Rasio rega marang pendapatan|Turnstone Biologics Corp. - Kapitalisasi marang volume dodolan|VCNX: Multiplikator P/S|Rasio kapitalisasi marang pendapatan HARP